Skip to main content

Table 1 Demographics and clinical characteristics of patients

From: Dynamic serum biomarkers to predict the efficacy of PD-1 in patients with nasopharyngeal carcinoma

Characteristic cohort (n = 54)

Training cohort (n = 106)

No. (%)

Validation

No. (%)

p

Age, y

 Median (range)

47(24–73)

43(19–78)

0.9718

Sex

 Female

29 (27.36)

18 (33.33)

0.4660

 Male

77 (72.64)

36 (66.67)

Recurrence

 Yes

50 (47.17)

23 (42.59)

0.6180

 No

56(52.83)

31 (57.41)

ECOG

 0

6 (5.66)

9 (16.67)

0.1930

 1

98 (92.45)

45 (83.33)

 2

2 (1.89)

0 (0.00)

Histological type

 Poorly differentiated type

3 (2.83)

6 (11.11)

0.0620

 Undifferentiated type

103 (97.17)

48 (88.89)

Clinical stage

 II–III

38 (35.85)

19 (35.19)

0.1430

 IVa

21 (19.81)

15 (27.78)

 IVb

36(33.96)

12 (22.22)

 IVc

11 (10.38)

8 (14.81)

Tumor stage

 T0–2

24 (22.64)

12 (22.22)

0.9520

 T3–4

82 (77.36)

42 (77.78)

Node stage

 N0–1

47 (44.34)

23 (42.59)

0.8670

 N2–3

59 (55.66)

31 (57.41)

Metastasis stage

 M0

49 (46.23)

28 (51.85)

0.5090

 M1

57 (53.77)

26(48.15)

Outcomes

 PR

24 (22.64)

10 (18.52)

0.0610

 SD

68 (64.15)

35 (64.81)

 PD

14 (13.21)

9 (16.67)

The PD1 drug

 Camrelizumab

16 (15.09)

2 (3.70)

0.2070

 Pembrolizumab

3 (2.83)

0 (0.00)

 Toripalimab

72 (67.93)

45 (83.33)

 Sintilimab

15 (14.15)

7 (12.97)

  1. ECOG Eastern Cooperative Oncology Group Performance Status, PR partial response, SD stable disease; PD progressive disease